Log in
Enquire now

Clinical Studies Sponsored by Neurocrine Biosciences

Clinical Studies Sponsored by Neurocrine Biosciences
Clinical Studies Sponsored by University of Milan
Clinical Studies Sponsored by Hebrew University of Jerusalem
Clinical Studies Sponsored by GE Healthcare
List of ProQR Therapeutics patents
List of companies in Shepherd Ventures's investment portfolio
Clinical Studies where
Trial Sponsor
is
Name
Description
NCT Number
Health Conditions in Trial
Clinical Trial Start Date
Study Completion Date
Clinical Trial Study Type
‌
A Study to Evaluate NBI-6024 in Adult and Adolescent Patients With New Onset of Type 1 Diabetes Mellitus

NCT00873561
2001
2006
Interventional
‌
Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS)

NCT00079495
Multiple sclerosis
Multiple sclerosis
2003
2005
Interventional
‌
An Exploratory Study of NBI-34060 Capsules and Next Day Functioning

NCT00525941
Insomnia
Insomnia
2007
2008
Interventional
‌
Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854 in Healthy Subjects

NCT01910480
2013
2013
Interventional
‌
Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents

NCT03062033
Tardive dyskinesia
Tardive dyskinesia
April 4, 2017
2018
Observational
‌
Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer

NCT00039052
Lung cancer
Lung cancer
Kidney cancer
Kidney cancer
‌
Breast Cancer
2002
2008
Interventional
‌
NBI-3001 Followed by Surgery in Treating Patients With Recurrent Glioblastoma Multiforme

NCT00014677
2001
2008
Interventional
‌
Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia

NCT01267188
Tardive dyskinesia
Tardive dyskinesia
2011
2011
Interventional
‌
Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada

NCT06312189
2024
2026
Interventional
‌
A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder

NCT06267846
Major depressive disorder
Major depressive disorder
2024
2025
Interventional
‌
Study Of Indiplon/Placebo With Sertraline In Insomnia Co-Existing With Depression

NCT00232167
‌
Depression
Insomnia
Insomnia
2005
2006
Interventional
‌
The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine

NCT03698331
September 14, 2018
April 3, 2019
Interventional
‌
Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome

NCT03530293
‌
Tourette syndrome
April 17, 2018
July 16, 2019
Interventional
‌
Opicapone Treatment Initiation Open-Label Study

NCT04787965
March 1, 2021
August 4, 2022
Observational
‌
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease

NCT04400331
September 18, 2020
2026
Interventional
‌
A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation

NCT03101293
April 4, 2017
May 26, 2017
Interventional
‌
Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia

NCT02349503
‌
Congenital adrenal hyperplasia
2015
2015
Interventional
‌
A Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive Treatment of Adult Participants With Negative Symptoms of Schizophrenia

NCT03382639
‌
Schizophrenia
January 4, 2018
January 12, 2021
Interventional
‌
A Study to Evaluate Efficacy, Tolerability, Pharmacodynamic and Pharmacokinetics of Multiple Oral Doses of TAK-831 in Adults With Schizophrenia

NCT03359785
‌
Schizophrenia
December 21, 2017
December 21, 2020
Interventional
‌
A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures

NCT05159908
November 8, 2021
August 21, 2023
Interventional
‌
Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome

NCT03444038
‌
Tourette syndrome
February 8, 2018
July 12, 2019
Interventional
‌
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Patients With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)

NCT04806451
‌
Congenital adrenal hyperplasia
June 24, 2021
2027
Interventional
‌
VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)

NCT03562494
Parkinson's disease
Parkinson's disease
October 17, 2018
2024
Interventional
‌
Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome

NCT02256475
Tourette syndrome
Tourette syndrome
2014
2015
Interventional
‌
Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia

NCT03891862
March 18, 2019
January 30, 2020
Interventional
Results per page:
57 results
0 selected
57 results
0 selected
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us